Date of Award

Spring 2022

Degree Name

Master of Medical Science (Physician Assistant)

Department

Physician Assistant; College of Health Sciences

First Advisor

Lisa Akselrad, MMS PA-C

Abstract

For decades, women wishing to treat their symptomatic uterine fibroids while preserving their fertility have been limited in options for intervention, with the myomectomy, a surgical procedure with possibility for recurrence, being the mainstay of treatment. In the last decade, various potential pharmacologic options have been studied and tested in the management of symptomatic uterine fibroids, with a focus on outcomes of reduction in pain and heavy bleeding. Ulipristal acetate seems to be the most promising option to come out of this research, however, a potential serious side effect related to the liver is keeping it from approval while this is investigated further. Until then, Elagolix has been FDA approved under the name Oriahnn for treatment of heavy bleeding caused by uterine fibroids and seems to be efficacious in achieving that end.

Download

Share

COinS
 

Treatment of Uterine Fibroids

For decades, women wishing to treat their symptomatic uterine fibroids while preserving their fertility have been limited in options for intervention, with the myomectomy, a surgical procedure with possibility for recurrence, being the mainstay of treatment. In the last decade, various potential pharmacologic options have been studied and tested in the management of symptomatic uterine fibroids, with a focus on outcomes of reduction in pain and heavy bleeding. Ulipristal acetate seems to be the most promising option to come out of this research, however, a potential serious side effect related to the liver is keeping it from approval while this is investigated further. Until then, Elagolix has been FDA approved under the name Oriahnn for treatment of heavy bleeding caused by uterine fibroids and seems to be efficacious in achieving that end.